EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Tumor immune microenvironment dynamics and outcomes of prognosis in non‐muscle‐invasive bladder cancer

Rei Kamitani, Nobuyuki Tanaka iD, Tadatsugu Anno, Tetsushi Murakami, Tsukasa Masuda, Yota Yasumizu iD, Toshikazu Takeda, Shinya Morita, Takeo Kosaka iD, Shuji Mikami, Kazuhiro Matsumoto iD, Mototsugu Oya iD

Cancer Science · 2024-12 · 115 (12) · 3963-3972

DOI: 10.1111/cas.16333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 11.10.2024. Verfasst von Rei Kamitani und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Princess Takamatsu Cancer Research Fund, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Agents that target PD‐1 and PD‐L1 have been developed in the treatment of bladder cancer (BC). However, the diversity of immune cell infiltration in non‐muscle‐invasive BC (NMIBC) and the dynamics of the microenvironment as it progresses to muscle‐invasive/metastatic disease remains unknown. To assess tumor immune activity, hierarchical clustering was applied to 159 BC samples based on cellular positivity for the defined immune cellular markers (CD3/CD4/CD8/FOXP3/CD20/PD‐1/PD‐L1/LAG3/TIGIT), divided into two clusters. There was a “hot cluster” (25%) consisting of patients with a high expression of these markers and a “cold cluster” (75%) comprising those without. The expression of CD39, CD44, CD68, CD163, IDO1, and Ki67 was significantly higher in tumors in the hot cluster. Immunologically, high‐grade T1 tumors were significantly hotter, whereas tumors that had progressed to muscle invasion turned cold. However, a certain number of high‐grade NMIBC patients were in the cold cluster, and these patients had a significantly higher risk of disease progression. Using an externally available TCGA dataset, RB1 and TP53 alterations were more frequently observed in TCGA hot cluster; rather FGFR3 , KDM6A , and KMT2A alterations were common in TCGA cold/intermediate cluster. Analyses of recurrent tumors after BCG therapy revealed that tumor immune activity was widely maintained before and after treatment, and high FGFR3 expression was detected after recurrence in tumors initially classified into the cold cluster. Collectively, we revealed the dynamics of the tumor microenvironment in BC as a whole and identified candidate molecules as therapeutic targets for recurrent NMIBC, e.g., after BCG therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsTumor MicroenvironmentHumansMaleFemaleAgedPrognosisMiddle AgedBiomarkers, TumorAged, 80 and overDisease ProgressionRetinoblastoma Binding ProteinsNeoplasm InvasivenessTumor Suppressor Protein p53Lymphocytes, Tumor-InfiltratingHistone DemethylasesAntigens, CDNeoplasm Recurrence, LocalAdultNon-Muscle Invasive Bladder NeoplasmsUbiquitin-Protein Ligases

Stichwörter der Autor:innen

FGFR3PD‐1PD‐L1bladder cancermicroenvironment

Substanzen

Biomarkers, TumorRB1 protein, humanRetinoblastoma Binding ProteinsKDM6A protein, humanTumor Suppressor Protein p53Histone DemethylasesAntigens, CDTP53 protein, humanUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Diagnostic Pathology, Keio University Hospital, Tokyo, Japan.
  • Department of Diagnostic Pathology, National Hospital Organization Saitama Hospital, Saitama, Japan.

ORCID-Profile: Nobuyuki Tanaka, Yota Yasumizu, Takeo Kosaka, Kazuhiro Matsumoto, Mototsugu Oya

Förderung

  • Japan Society for the Promotion of Science
  • Princess Takamatsu Cancer Research Fund
  • Takeda Science Foundation
  • Foundation for Promotion of Cancer Research Japan
  • Keio Gijuku Academic Development Fund
  • SGH Foundation for Cancer Research

Zitieren

APA

Kamitani, R., Tanaka, N., Anno, T., Murakami, T., Masuda, T., Yasumizu, Y., Takeda, T., Morita, S., Kosaka, T., Mikami, S., Matsumoto, K., & Oya, M. (2024). Tumor immune microenvironment dynamics and outcomes of prognosis in non‐muscle‐invasive bladder cancer. Cancer Science, 115(12), 3963-3972. https://doi.org/10.1111/cas.16333

Vancouver

Kamitani R, Tanaka N, Anno T, Murakami T, Masuda T, Yasumizu Y, et al. Tumor immune microenvironment dynamics and outcomes of prognosis in non‐muscle‐invasive bladder cancer. Cancer Science. 2024;115(12):3963-3972. doi:10.1111/cas.16333

BibTeX
@article{Kamitani2024,
  author = {Kamitani, Rei and Tanaka, Nobuyuki and Anno, Tadatsugu and Murakami, Tetsushi and Masuda, Tsukasa and Yasumizu, Yota and Takeda, Toshikazu and Morita, Shinya and Kosaka, Takeo and Mikami, Shuji and Matsumoto, Kazuhiro and Oya, Mototsugu},
  title = {Tumor immune microenvironment dynamics and outcomes of prognosis in non‐muscle‐invasive bladder cancer},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {12},
  pages = {3963--3972},
  doi = {10.1111/cas.16333}
}
Kostenlos starten →